主任医师、博士生导师，中国科学技术大学附属第一医院（安徽省立医院）变态反应与临床免疫科主任，安徽省学术技术带头人，安徽省医学会临床流行病学分会主任委员，安徽省医学会风湿病学分会副主任委员，中国医师协会风湿病学分会痛风学组委员，安徽省医师协会痛风学组组长。
一、学习及工作经历
1990年-1995年，安徽医科大学，临床医学专业，学士；
2002年-2005年，安徽医科大学，内科学（风湿病）专业，硕士；
2008年-2011年，安徽医科大学，流行病与卫生统计学专业，博士；
2014年-2015年，美国霍普金斯大学，免疫学专业，博士后；
1995年-至今，中国科学技术大学附属第一医院（安徽省立医院），医师
二、学术成果及影响
致力于内科学风湿病专业临床、教学与科学研究工作30年，培养毕业博士、硕士研究生20余名。主要学术成就：发现ATP是痛风的第二致病信号，其受体P2X7R功能调控痛风发病，改写了痛风发病机制；发现调节性T细胞在急慢性痛风转换中起关键作用，完善了痛风缓解机制，为迁延不愈的难治性痛风找到了新的治疗靶点，也为进一步研究急慢性炎症的转化换机制奠定了基础。研究成果获省级科学技术奖3项；在Cancer Discov、Immunity、J Exp Med等杂志发表SCI论文120多篇，被引用4000余次，H指数30。
三、在研项目(仅限于主要负责人)
项目名称、来源、经费指标卡号 | 总经费(万元) | 起止日期 |
炎症细胞焦亡关键调控靶点的鉴定及其抑制剂的筛选和验证，中央高校基本科研业务费专项资金资助（YD9110002017） | 100 | 2023-01至2025-12 |
四、主要研究方向（招生专业）及内容
生物学
1、炎症信号传导
2、免疫细胞分化调控
临床医学
1、内科学
1) 过敏与风湿性疾病的代谢、炎症、免疫相互调控的机制；
2) 过敏与风湿性疾病精准治疗的靶点及其干预药物的筛选和验证；
五、代表性论文（近五年）
1. Luo C, Liu X, Liu Y, Shao H, Gao J, Tao J*. Upregulation of CD39 During Gout Attacks Promotes Spontaneous Remission of Acute Gouty Inflammation. Inflammation. 2023 Dec 6. doi: 10.1007/s10753-023-01936-w. Epub ahead of print. PMID: 38055119.
2. Zhang H, Gao J, Tang Y, Jin T*, Tao J*. Inflammasomes cross-talk with lymphocytes to connect the innate and adaptive immune response. J Adv Res. 2023 Jan 18:S2090-1232(23)00025-5.
3. Li X, Wan A, Liu Y, Li M, Zhu Z, Luo C, Tao J*. P2X7R Mediates the Synergistic Effect of ATP and MSU Crystals to Induce Acute Gouty Arthritis. Oxid Med Cell Longev. 2023 Jan 12;2023:3317307.
4. Gao J, Zhang H, Yang Y, Tao J*. Therapeutic Potential of Targeting the NLRP3 Inflammasome in Rheumatoid Arthritis. Inflammation. 2023 Jun;46(3):835-852.
5. Liu Y, Feng S, Liu X, Tang Y, Li X, Luo C, Tao J*. IFN-beta and EIF2AK2 are potential biomarkers for interstitial lung disease in anti-MDA5 positive dermatomyositis. Rheumatology (Oxford). 2023 Mar 13:kead117.
6. Li MY, Fang X, Ma Y, Pan XY, Dai XJ, Li XM, Li XL, Wang YP, Tao JH*, Li XP*. The functional change of the P2X7R containing the Ala348 to Thr polymorphism is associated with the pathogenesis of gout. Sci Rep. 2023 Apr 5;13(1):5603.
7. Wu ZD, Chen C, He YS, Chen Y, Feng YT, Huang JX, Yin KJ, Wang J, Tao JH*, Pan HF*. Association between air pollution exposure and outpatient visits for dermatomyositis in a humid subtropical region of China: a time-series study. Environ Geochem Health. 2023 Aug;45(8):6095-6107.
8. Li X, Liu Y, Luo C, Tao J*. Z1456467176 alleviates gouty arthritis by allosterically modulating P2X7R to inhibit NLRP3 inflammasome activation. Front Pharmacol. 2022 Aug 16;13:979939.
9. Zhang H, Gao J, Fang W, Tang Y, Fang X, Jin T*, Tao J*. Role of NINJ1 in Gout Flare and Potential as a Drug Target. J Inflamm Res. 2022 Sep 28;15:5611-5620.
10. Wan A, Zhao WD, Tao JH*. Causal effects of systemic lupus erythematosus on endometrial cancer: A univariable and multivariable Mendelian randomization study. Front Oncol. 2022 Oct 3;12:930243.
11. Wu J, Ye Q, Fang L, Deng L, Liao T, Liu B, Lv X, Zhang J, Tao J*, Ye D*. Short-term association of NO2 with hospital visits for chronic kidney disease and effect modification by temperature in Hefei, China: A time series study. Ecotoxicol Environ Saf. 2022 Jun 1;237:113505.
12. Liu Y, Tao X, Tao J*. Strategies of Targeting Inflammasome in the Treatment of Systemic Lupus Erythematosus. Front Immunol. 2022 May 18;13:894847.
13. Dai X, Fang X, Xia Y, Li M, Li X, Wang Y, Tao J*, Li X*. ATP-Activated P2X7R Promote the Attack of Acute Gouty Arthritis in Rats Through Activating NLRP3 Inflammasome and Inflammatory Cytokine Production. J Inflamm Res. 2022 Feb 23;15:1237-1248.
14. Li X, Gao J, Tao J*. Purinergic Signaling in the Regulation of Gout Flare and Resolution. Front Immunol. 2021 Dec 1;12:785425. doi: 10.3389/fimmu.2021.785425.
15. Dong Y, Li X, Liu Y, Gao J, Tao J*. The molecular targets of taurine confer anti-hyperlipidemic effects. Life Sci. 2021 Aug 1;278:119579.
16. Zhang H, Zahid A, Ismail H, Tang Y, Jin T*, Tao J*. An overview of disease models for NLRP3 inflammasome over-activation. Expert Opin Drug Discov. 2021 Apr;16(4):429-446.
17. Zhang H, Tang Y, Tao J*. Sex-Related Overactivation of NLRP3 Inflammasome Increases Lethality of the Male COVID-19 Patients. Front Mol Biosci. 2021 Jun 4;8:671363.
18. Zahid A, Li B, Kombe AJK, Jin T*, Tao J*. Pharmacological Inhibitors of the NLRP3 Inflammasome. Front Immunol. 2019 Oct 25;10:2538.
六、联系方式
E-mail: taojinhui@ustc.edu.cn
电话：0551-62224162